Evidence map›Paper›PMID 38096952›Full record

ArticleKidney international2024

A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis.

Charalampos Charalampous, Surendra Dasari, Ellen McPhail, Jason D Theis, Julie A Vrana, Angela Dispenzieri, Nelson Leung, Eli Muchtar, Morie Gertz, Marina Ramirez-Alvarado and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Kidney international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Pathogenesis and kidney prognosis of renal amyloidosis.Cellular and molecular life sciences : CMLS · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage.Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2025
    Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Charalampos CharalampousDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Surendra DasariDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Ellen McPhailDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Jason D TheisDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Julie A VranaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Nelson LeungDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Eli MuchtarDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Morie GertzDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Marina Ramirez-AlvaradoDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA.
Taxiarchis KourelisDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Kourelis.taxiarchis@mayo.edu.
Mayo Clinic · USMayo Clinic in Florida · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
Paul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7M
NCI NIH HHS K12 CA090628NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

The mechanisms of tissue damage in kidney amyloidosis are not well described. To investigate this further, we used laser microdissection-mass spectrometry to identify proteins deposited in amyloid plaques (expanded proteome) and proteins overexpressed in plaques compared to controls (plaque-specific proteome). This study encompassed 2650 cases of amyloidosis due to light chain (AL), heavy chain (AH), leukocyte chemotactic factor-2-type (ALECT2), secondary (AA), fibrinogen (AFib), apo AIV (AApoAIV), apo CII (AApoCII) and 14 normal/disease controls. We found that AFib, AA, and AApoCII have the most distinct proteomes predominantly driven by increased complement pathway proteins. Clustering of cases based on the expanded proteome identified two ALECT2 and seven AL subtypes. The main differences within the AL and ALECT2 subtypes were driven by complement proteins and, for AL only, 14-3-3 family proteins (a family of structurally similar phospho-binding proteins that regulate major cellular functions) widely implicated in kidney tissue dysfunction. The kidney AL plaque-specific proteome consisted of 24 proteins, including those implicated in kidney damage (α1 antitrypsin and heat shock protein β1). Hierarchical clustering of AL cases based on their plaque-specific proteome identified four clusters, of which one was associated with improved kidney survival and was characterized by higher overall proteomic content and 14-3-3 proteins but lower levels of light chains and most signature proteins. Thus, our results suggest that there is significant heterogeneity across and within amyloid types, driven predominantly by complement proteins, and that the plaque protein burden does not correlate with amyloid toxicity.

Indexed as

AmyloidosisAtrial FibrillationRenal InsufficiencyAmyloidComplement System ProteinsHumansKidneyProteomeProteomicsAmyloidComplement System ProteinsProteomeamyloidosisprotein aggregationproteomics

Identifiers

PMID38096952
PMCPMC10922603
OpenAlexW4389627484

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.